治療診斷學市場規模、佔有率及成長分析（依產品、技術、疾病、最終用戶及地區分類）－2025-2032年產業預測

預計到 2023 年，全球治療診斷學市場規模將達到 22 億美元，到 2024 年將達到 25 億美元，到 2032 年將達到 68.8 億美元，在預測期（2025-2032 年）內，複合年成長率為 13.5%。

全球治療診斷學市場正經歷強勁成長，這主要得益於人們對個人化醫療日益成長的需求以及包括癌症和心血管疾病在內的慢性病盛行率不斷上升。將診斷和治療功能整合到單一平台，既能提高治療效果，又能降低醫療成本。影像學和生物標記的創新進一步拓展了治療診斷學在已開發市場和新興市場的應用。然而，高昂的研發成本、複雜的監管流程以及低收入群體認知度不足等挑戰依然存在，阻礙了其廣泛應用。此外，有限的保險覆蓋範圍和對專用基礎設施的需求也限制了這些解決方案在標準臨床環境中的擴充性。透過政策支持、研發投資和策略合作來克服這些障礙，對於市場的持續成長至關重要。

全球治療診斷學市場促進因素

對個人化醫療日益成長的需求是治療診斷學市場的關鍵驅動力。醫療系統正擴大採用整合診斷和治療調查方法，從而能夠根據每位患者獨特的基因和分子特徵量身定做治療方案。這種向個人化醫療的轉變不僅提高了治療效果，還最大限度地減少了副作用，最終促進了患者照護的改善。透過關注個人需求，治療診斷學方法正在改變醫療格局，帶來更有效、以病人為中心的治療。因此，醫療領域對個性化治療方案的需求正在不斷成長。

限制全球治療診斷學市場發展的因素

全球治療診斷學市場因其高昂的成本結構而面臨許多挑戰。對先進成像技術、專用試劑和高技能人員的需求，可能會限制這些先進成像產品的可及性，尤其是在醫療資源匱乏的偏遠地區。治療診斷學解決方案的高昂成本會給醫療系統帶來壓力，阻礙報銷模式的製定，並帶來政治風險，從而進一步延緩這些創新技術融入常規臨床實踐的進程。因此，這些經濟障礙可能會顯著限制治療診斷學在患者照護中的廣泛應用。

全球治療診斷學市場趨勢

由於人工智慧 (AI) 與治療系統的融合，全球治療診斷學市場正經歷顯著成長。 AI 增強的診斷能力正在推動個人化治療策略的製定，從而實現更個人化的患者照護。借助包括影像分析和治療反應預測建模在內的先進數據分析技術，該市場正日益聚焦於精準醫療。 AI 與治療診斷學的創新結合提供了即時、數據驅動的洞察，從而能夠有效管理複雜疾病並最佳化臨床療效。隨著該領域的不斷發展，它將繼續在全球醫療服務轉型和改善患者預後方面發揮引領作用。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管環境

治療診斷學市場規模（依產品分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 診斷造影顯影劑
• 放射性藥物和標靶治療
• 體外診斷/生物標記篩檢試劑盒
• 軟體和服務

按技術分類的治療診斷學市場規模及複合年成長率（2025-2032 年）

• 市場概覽
• 分子影像（PET/SPECT）
• 放射性配體療法
• 基於奈米顆粒的治療診斷學
• 生物標記驅動的伴隨診斷

依疾病分類的治療診斷學市場規模及複合年成長率（2025-2032 年）

• 市場概覽
• 腫瘤學
• 神經病學
• 循環系統疾病
• 免疫/發炎性疾病
• 其他

依最終用戶分類的治療診斷學市場規模及複合年成長率（2025-2032 年）

• 市場概覽
• 醫院及癌症治療中心
• 診斷檢查室
• 研究和學術機構
• 治療診斷學中心

治療診斷學市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2024 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2022-2024年營收年比比較

主要企業簡介

• Bayer AG
• GE Healthcare
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Novartis AG
• Telix Pharmaceuticals Limited
• Curium Pharma
• Advanced Accelerator Applications（AAA）
• Bracco Imaging SpA
• Lantheus Holdings
• NanoString Technologies, Inc.
• Roche Holding AG
• Qiagen NV
• Illumina Inc.
• Myriad Genetics, Inc.
• AbbVie Inc.
• Philips Healthcare
• Endocyte, Inc.
• NorthStar Medical Radioisotopes LLC

結論與建議

Global Theranostics Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.5 billion in 2024 to USD 6.88 billion by 2032, growing at a CAGR of 13.5% during the forecast period (2025-2032).

The global theranostics market is experiencing robust growth, driven by rising demand for personalized medicine and the increasing prevalence of chronic diseases, including cancer and cardiovascular conditions. The integration of diagnostic and therapeutic functions into a single platform enhances treatment efficacy while offering cost-saving benefits in healthcare. Innovations in imaging and biomarkers further broaden the scope of theranostic applications across both developed and emerging markets. However, several challenges persist, including high development costs, intricate regulatory processes, and limited awareness in low-income areas, which hinder widespread adoption. Additionally, restricted reimbursement and the necessity for specialized infrastructure constrain the scalability of these solutions in standard clinical practices. Addressing these barriers through policy support, investment in research and development, and strategic collaborations is crucial for sustainable market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Theranostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Theranostics Market Segments Analysis

Global Theranostics Market is segmented by Product, Technology, Disease, End-User and region. Based on Product, the market is segmented into Diagnostic Imaging Agents, Radiopharmaceuticals & Targeted Therapeutics, IVD/Biomarker Screening Kits and Software & Services. Based on Technology, the market is segmented into Molecular Imaging (PET/SPECT), Radioligand Therapy, Nanoparticle-based Theranostics and Biomarker-driven Companion Diagnostics. Based on Disease, the market is segmented into Oncology, Neurology, Cardiovascular Diseases, Immunological/Inflammatory Disorders and Others. Based on End-User, the market is segmented into Hospitals & Cancer Treatment Centres, Diagnostic Laboratories, Research & Academic Institutes and Theranostics Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Theranostics Market

The surge in demand for personalized medicine stands as a pivotal force propelling the theranostics market forward. Healthcare systems are progressively adopting integrated diagnostic and therapeutic methodologies, enabling treatments to be tailored to the unique genetic and molecular characteristics of each patient. This shift towards personalized medicine not only enhances therapeutic outcomes but also minimizes adverse effects, ultimately fostering improved patient care. By focusing on individual needs, the theranostics approach is reshaping the landscape of healthcare, making it more effective and patient-centric. As a result, the drive for personalized treatment solutions continues to gain momentum in the medical field.

Restraints in the Global Theranostics Market

The global theranostics market faces significant challenges due to its substantial cost structure. The need for sophisticated imaging technologies, unique reagents, and a highly skilled workforce can restrict access to these advanced imaging products, particularly in underserved and rural communities. High expenses linked to theranostic solutions can strain healthcare systems, hindering the progress of reimbursement models and introducing political risks that may further delay the integration and acceptance of these innovations into everyday clinical practice. As a result, these financial barriers can significantly limit the potential for widespread utilization of theranostics in patient care.

Market Trends of the Global Theranostics Market

The Global Theranostics market is experiencing significant growth driven by the integration of artificial intelligence into therapeutic systems. AI-enhanced diagnostic capabilities facilitate tailored treatment strategies, enabling a more personalized approach to patient care. By leveraging advanced data analytics, including the interpretation of imaging and predictive modeling of therapeutic responses, the market is increasingly focused on precision medicine. This innovative intersection of AI and theranostics allows for real-time, data-driven insights that effectively manage complex diseases and optimize clinical outcomes. As this field continues to advance, it positions itself at the forefront of transforming healthcare delivery and improving patient outcomes globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Theranostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Diagnostic Imaging Agents
• Radiopharmaceuticals & Targeted Therapeutics
• IVD/Biomarker Screening Kits
• Software & Services

Global Theranostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Molecular Imaging (PET/SPECT)
• Radioligand Therapy
• Nanoparticle-based Theranostics
• Biomarker-driven Companion Diagnostics

Global Theranostics Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurology
• Cardiovascular Diseases
• Immunological/Inflammatory Disorders
• Others

Global Theranostics Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals & Cancer Treatment Centres
• Diagnostic Laboratories
• Research & Academic Institutes
• Theranostics Centres

Global Theranostics Market Size & CAGR (2025-2032)

• North America (Product, Technology, Disease, End-User)
  • US
  • Canada
• Europe (Product, Technology, Disease, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Disease, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Disease, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Disease, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Telix Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (AAA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endocyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NorthStar Medical Radioisotopes LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations